Aim: To assess efficacy of vaccine against viral hepatitis B (VHB) in adults after achievement of acute leukemia (AL) remission.
Material And Methods: Specific prevention of VHB was made in 30 AL patients with recombinant vaccine Engerix B by two schemes: 0-1-2-12 and 0-1-2-6 months with double adult dose 40 mcg. Efficacy of vaccination was evaluated by the titer of antibodies to HBs-Ag (HBs-Ab) 1 month after each injection of the vaccine. The control group consisted of 36 patients. Follow-up was 6 months to 10 years.
Results: Vaccine prophylaxis of VHB in AL remission resulted in appearance of the protective antibody titer after the forth vaccine injection in 50% patients. Out of 30 vaccinated patients 2 (6.7%) got infected with HBV 3 and 5 years after onset of the disease. Markers of HBV replication were detected in 8 (22%) of 36 patients.
Conclusion: Vaccine prophylaxis of VHB in adult patients in AL remission was effective in 93.3% of the vaccinated patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- The report updates the 1999 CDC Framework for Program Evaluation in Public Health to include new advancements and lessons learned in evaluation and public health.
- The 2024 framework introduces a nonprescriptive tool with six steps for effective evaluation planning and implementation, while emphasizing engagement, equity, and learning from insights.
- It serves as a guide for designing evaluations applicable to various programs, enhancing evidence-based decision-making, and improving program outcomes across different areas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!